Approval of unaudited Financial result of the Company for the quarter and nine month ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Archit Organosys Ltd's board approved its Q3 FY26 and nine-month ended December 31, 2025 unaudited financial results on February 7, 2026. Revenue from operations for Q3 stood at Rs. 3,839.81 lakhs, up about 48% from Rs. 2,587.10 lakhs in the same quarter last year. For the nine months, revenue rose to Rs. 10,445.36 lakhs from Rs. 8,241.59 lakhs, a growth of roughly 27%. Net profit for Q3 more than doubled to Rs. 243.48 lakhs (from Rs. 101.21 lakhs), and nine-month PAT nearly doubled to Rs. 600.99 lakhs (from Rs. 303.36 lakhs). EPS for Q3 came in at Rs. 1.19 versus Rs. 0.49 a year ago. Statutory auditors G.K. Choksi & Co. issued an unmodified limited review report with no qualifications.
Strong topline and bottomline growth year-on-year, with no auditor qualifications, is a positive signal for shareholders and likely supportive of the stock. Investors should note the company recognized a provision for defined benefit obligations following the implementation of the new Labour Codes, which may slightly affect future employee cost accounting.